nafamostat has been researched along with Jaundice in 1 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
Jaundice: A clinical manifestation of HYPERBILIRUBINEMIA, characterized by the yellowish staining of the SKIN; MUCOUS MEMBRANE; and SCLERA. Clinical jaundice usually is a sign of LIVER dysfunction.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Endo, Y | 1 |
| Oka, T | 1 |
| Hanasawa, K | 1 |
| Yoshioka, T | 1 |
| Tani, T | 1 |
| Nakane, Y | 1 |
| Kodama, M | 1 |
1 other study available for nafamostat and Jaundice
| Article | Year |
|---|---|
Applications of protease inhibitor to hemoperfusion and plasma exchange as a regional anticoagulant.
Topics: Animals; Anticoagulants; Benzamidines; Dogs; Extracorporeal Circulation; Guanidines; Humans; Jaundic | 1985 |